Immunotherapeutic effect of the lactobacillus vaccine, Solco Trichovac, in trichomoniasis is not mediated by antibodies cross reacting with Trichomonas vaginalis

A GOMBOŠOVÁ, P DEMEŠ, AND M VALENT
From the Institute of Parasitology, Comenius University, Bratislava, Czechoslovakia.

SUMMARY According to the producers of the lactobacillus vaccine, SolcoTrichovac, its therapeutic effect in trichomoniasis is achieved by antibodies that are induced by the vaccination and cross react with Trichomonas vaginalis. Common antigens of Lactobacillus acidophilus from SolcoTrichovac vaccine and T vaginalis were therefore sought by three different seroreactions. Immune serum against L acidophilus obtained by vaccinating two healthy human volunteers and two rabbits with the original SolcoTrichovac vaccine, as well as hyperimmune rabbit antiserum to T vaginalis, were tested with each of the two micro-organisms. No evidence of antigenic similarity between L acidophilus and T vaginalis was obtained with either serum in any of the three serological tests. A non-specific immunostimulatory effect therefore seems to be a more probable explanation of the mode of action of SolcoTrichovac vaccine.

Introduction

At the end of the 1970s a lactobacillus vaccine, SolcoTrichovac, was introduced by the Swiss company, Solco (Basel), as a new treatment of urogenital trichomoniasis in man. The systemic vaccine, which consists of eight inactivated aberrant strains of Lactobacillus acidophilus isolated from patients infected with Trichomonas vaginalis, should represent an alternative to nitroimidazole chemotherapy. According to various authors, the efficacy of SolcoTrichovac immunotherapy is 90-100%.

Hungarian workers first reported attempts to control urogenital trichomoniasis by immunisation with inactivated lactobacilli, which were isolated either from patients with trichomoniasis or from healthy virgins. As with streptococcal or trichomonal vaccines, Solco Trichovac was more effective at resolving clinical signs than in reducing the number of parasites in the vagina.

The precise mode of action of the bacterial vaccines against trichomoniasis is poorly understood. The hypothesis proposed by the makers of SolcoTrichovac is that the vaccine induces cross reacting antibodies against abnormal lactobacilli and T vaginalis without adversely affecting the growth of normal lactobacilli in the vagina. Clinical improvement as well as the elimination of T vaginalis should therefore occur in the course of vaccination.

The concept of antigenic similarity of two such unrelated and serologically variable groups of organisms as lactobacilli and trichomonads is rather surprising. The aim of the present study was therefore to assess the serological cross reactivity between lactobacilli from SolcoTrichovac vaccine and T vaginalis.

Patients, materials, and methods

ISOLATION AND CULTIVATION OF T VAGINALIS
Material for the isolation of T vaginalis was obtained from the posterior fornix of the vagina of unselected patients attending this institute. The parasites were grown in Diamond’s tripticase, yeast extract, and maltose (TYM) medium supplemented with 10% heat inactivated beef serum at 37°C. For axenisation, antibiotics (1000 IU penicillin G and 1 mg streptomycin sulphate/ml) were added to the medium in three subsequent subcultures. Axenic cultures were maintained by serial passages at two day intervals in the same medium without antibiotics. For the preparation of trichomonal antigen, flagellates were transferred three times in Diamond’s TYM medium without agar. We used 24 to 48 hour old cultures derived from the last transfer.

Address for reprints: Dr P Demeš, Institute of Parasitology, Comenius University, Palisády 40, 811 06 Bratislava, Czechoslovakia
Accepted for publication 21 July 1985

Genitourin Med 1986; 62:107-10
PREPARATION OF ANTISERA

Two human volunteers (a woman and a man, both aged 29) with no history of trichomoniasis were immunised with SolcoTrichovac vaccine according to the schedule recommended by the producers. The vaccine was administered by intramuscular injection in three separate doses at intervals two weeks apart. Each injection consisted of 0.5 ml vaccine containing at least $7 \times 10^8$ inactivated micro-organisms of eight strains of *L. acidophilus*. Control serum samples were collected before immunisation, and immune serum samples two weeks after the third dose.

Rabbit antisera to lactobacillus was obtained by immunising two silver rabbits (about 3-5 kg in weight) with SolcoTrichovac vaccine given intravenously in three doses at weekly intervals. The immune serum was obtained by cardiac puncture one week after the final dose. Pooled preimmune serum served as a control. Antitrichomonal hyperimmune rabbit serum was prepared as described previously. Briefly, a male silver rabbit was immunised by increasing numbers of live *T. vaginalis* strain K-1 in five ml doses (containing $1 \times 10^7$, $1.5 \times 10^7$, $2 \times 10^7$, $2.5 \times 10^7$, or $2.5 \times 10^8$ cells) at weekly intervals. The rabbit was bled two weeks after the final injection. All serum samples were inactivated at 56°C for 30 minutes and stored at -20°C.

PREPARATION OF ANTIGENS

*T. vaginalis* antigen for serological testing was prepared from equal concentrations of six different strains cultivated in vitro for a maximum of two weeks. Twenty four to 48-hour-old cultures were centrifuged at $800 \times g$ for 10 minutes and washed three times in phosphate buffered saline (PBS), pH 7.2. Washed organisms were used as living antigen in the agglutination tests. For the indirect immunofluorescence assay a small drop of trichomonal suspension was spread on each of the ten circles marked on a Teflon covered slide. The slides were air dried, fixed in acetone for 10 minutes, and either used immediately or stored at -20°C until used. Lactobacillus antigen for indirect immunofluorescence assay was prepared from cells of the SolcoTrichovac original vaccine diluted 1:5 with PBS by the same procedure as was used for *T. vaginalis* antigen.

*T. vaginalis* soluble antigen for indirect haemagglutination was prepared by disrupting the washed cells by repeatedly (10 times) freezing them in liquid nitrogen and thawing at 40°C. The homogenate was centrifuged at 13 000 $\times g$ for 20 minutes and the supernatant was stored at -20°C. The protein concentration of antigen estimated by Lowry's method was 50 mg/l.

SEROLOGICAL REACTIONS

Agglutination

We used a micromodification of the assay described by Kott and Adler. Serial twofold dilutions of inactivated serum in 0.9% sodium chloride were set up in 0.1 ml volumes in plastic microtitration plates with U bottoms (Koh-I-Noor, Czechoslovakia). Equal volumes of a suspension of living washed trichomonads (at a concentration of $3 \times 10^8$/ml) were added. The plates were briefly agitated and incubated for two hours at room temperature. Agglutination was examined macroscopically. A positive reaction was associated with a characteristic pattern, the agglutinated cells forming a homogeneous covering at the bottom of the well. A negative reaction was distinguished by a compact spot of sedimented organisms. In these tests and in indirect immunofluorescence assays titres were expressed as the serum dilutions at the end point.

Indirect immunofluorescence assay

We performed indirect immunofluorescence assays with both trichomonal and lactobacillus antigen by a modification of the method described previously for *T. vaginalis*. Briefly, one drop of an appropriate dilution of the tested serum was added to each antigen spot. The slides were incubated at 20°C for 30 minutes in a moist chamber and washed in tap water for 10 minutes, in PBS for 15 minutes, and in tap water again for 10 minutes. After being dried at room temperature, each spot was covered with one drop of fluorescein isothiocyanate conjugated swine anti human or anti rabbit immunoglobulin (USOL, Prague) diluted 1:6 and 1:4 respectively. The slides were incubated and washed as above, immersed in an aqueous solution of Evan's blue (diluted 1:50 000) for 15 minutes at room temperature, and washed as before. After being dried the slides were mounted in buffered glycerol (diluted 9:1 in PBS) and examined with a Zeiss Fluoval microscope. Positive reactions were associated with distinct fluorescence of the cell surface.

Control slides were prepared using tested serum samples without conjugate and using conjugate without tested serum.

Indirect haemagglutination assay

Fresh sheep erythrocytes were centrifuged at $800 \times g$ for 10 minutes and washed three times in PBS. A 2.5% suspension of erythrocytes was mixed with an equal volume of tannic acid (diluted 1:120 000 in PBS) and incubated in an ice bath for 15 minutes. After being centrifuged at $800 \times g$ for 10 minutes and washed repeatedly in PBS, the sediment was incubated with an equal volume of soluble trichomonal antigen for 15 minutes at 37°C. Sensitised erythrocytes were washed in PBS and diluted to a 2.5% suspension in PBS.

We used a modification of the tube assay described...
**Immunotherapeutic effect of Solco Trichovac is not mediated by antibodies cross reacting with T vaginalis**

by Kott and Adler\(^\text{11}\) as follows: aliquots of tested serum at dilutions of 1:20 to 1:1280 in PBS were dispensed to each tube. After 0·05 ml sensitised erythrocytes had been added, the tubes were incubated for 24 hours at 20°C. Controls of sensitised erythrocytes and of individual serum samples with non-sensitised erythrocytes were included.

As the specific humoral responses in two human volunteers, as well as the responses of the two rabbits vaccinated with Solco Trichovac, were similar, parallel serum samples from the same species were pooled before use in further experiments.

**Results**

The antigenic relation of *T vaginalis* and *L. acidophilus* from Solco Trichovac vaccine was investigated by serological cross reactions of human and rabbit antiserum against each of the two micro-organisms.

Table I shows the specific antibody response against *L. acidophilus* generated in the course of vaccination with Solco Trichovac in the serum of healthy people and rabbits. Antibodies were not detected in rabbit hyperimmune antiserum to *T. vaginalis* by

T A B L E  I  \textbf{Antilactobacillus antibody titres by immunofluorescence assay of human and rabbit serum before and after vaccination with of SolcoTrichovac compared with those in rabbits immunised with Trichomonas vaginalis}

<table>
<thead>
<tr>
<th>Serum</th>
<th>Titres</th>
<th>Mean</th>
<th>Range</th>
<th>No of tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human:</td>
<td>Before vaccination</td>
<td>1/8</td>
<td>1/8-1/16</td>
<td>4</td>
</tr>
<tr>
<td>After vaccination</td>
<td></td>
<td>1/4-1/16</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Rabbit:</td>
<td>Before vaccination</td>
<td>1/32</td>
<td>1/16-1/64</td>
<td>3</td>
</tr>
<tr>
<td>After vaccination</td>
<td></td>
<td>1/16-1/64</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Immunised with <em>T. vaginalis</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TABLE II Antitrichomonal antibody titres in rabbit and human serum before and after vaccination with three doses of SolcoTrichovac compared with those in rabbits immunised with Trichomonas vaginalis**

<table>
<thead>
<tr>
<th>Serum</th>
<th>By immunofluorescence:</th>
<th>By haemagglutination:</th>
<th>By agglutination:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>Range</td>
<td>No of tests</td>
</tr>
<tr>
<td>Human</td>
<td>Before vaccination</td>
<td>1/7-6</td>
<td>0-1/16</td>
</tr>
<tr>
<td>After vaccination</td>
<td>1/6-8</td>
<td>0-1/16</td>
<td>6</td>
</tr>
<tr>
<td>Rabbit:</td>
<td>Before vaccination</td>
<td>1/1-25</td>
<td>1/1-1/2</td>
</tr>
<tr>
<td>After vaccination</td>
<td>1/3-2</td>
<td>1/2-1/4</td>
<td>4</td>
</tr>
<tr>
<td>Immunised with <em>T. vaginalis</em></td>
<td></td>
<td>1/256</td>
<td>1/64-1/512</td>
</tr>
</tbody>
</table>

immunofluorescence with *L. acidophilus* antigen, which indicated the absence of any antigenic similarity between the two micro-organisms.

The results of cross reacting tests of antiserum against *L. acidophilus* with trichomonal antigen, summarised in Table II, confirmed the lack of common antigens in the two organisms. No appreciable increase in the titres of antibodies against *T. vaginalis* after vaccination with Solco Trichovac could be detected by indirect immunofluorescence or haemagglutination assays or by agglutination in either serum. When, however, *T. vaginalis* antigen was tested with rabbit antiserum to *T. vaginalis*, high titres of specific antibodies were obtained in all serological tests. The increase compared with preimmune serum was 170-fold by indirect immunofluorescence assay, 64-fold by indirect haemagglutination assay, and 17-fold by agglutination.

**Discussion**

According to the manufacturers of the lactobacillus vaccine Solco Trichovac, its immunotherapeutic effect in trichomoniasis is accomplished by stimulation of the specific immune response in the serum and probably also in the cervical secretion of the host. The mode of action of the vaccine, as claimed by the producers, is the induction of antibodies against aberrant *L. acidophilus*, which cross react with *T. vaginalis* but not with physiological Doederlein's bacillus.\(^7\)\(^{13}\)\(^{14}\)

An increase in specific antilactobacillus agglutinins has been reported during the course of vaccination,\(^15\) but few data supporting the presence of cross reacting antibodies have yet been presented. The only evidence of common antigens in *T. vaginalis* and *L. acidophilus* has been obtained by Stojković\(^16\) and Bonilla-Musoles et al\(^17\) using indirect immunofluorescence assays.

In our experiments we failed to show any antigenic relation between lactobacilli from Solco Trichovac.
and several strains of *T. vaginalis*. No increase of antitrichomonal antibodies due to the vaccination, performed according to the original schedule, could be detected by any test in either human or rabbit serum. Moreover, rabbit antiserum to *T. vaginalis* did not react with *L. acidophilus* antigen in the indirect immunofluorescence assay, which suggested the absence of any common antigen in *T. vaginalis* and *L. acidophilus* from SolcoTrichovac. The weak positivity of all preimmune serum samples to *T. vaginalis* was probably due to the presence of natural antibodies against *T. vaginalis* in normal serum, which have been reported by several authors.18–20

In our experiments we recorded only a slight increase in titre of specific antibodies against *L. acidophilus* in both human and rabbit serum after vaccination with SolcoTrichovac. This finding confirms the low immunogenicity of lactobacilli.21

As both *L. acidophilus* and *T. vaginalis* occur in numerous serotypes,21–23 similarity of the two organisms seems to be very unlikely. Moreover, Doederlein flora comprise several species of lactobacillus, with interspecific as well as intraspecific serological differences.24,25

Our results and the data discussed above do not support the claim of the manufacturers of SolcoTrichovac. Nevertheless, the clinical effect reported so far is remarkable.1 If it is confirmed, a different explanation for the mode of action of the vaccine will have to be sought by further investigations of the microbial interactions in the vagina as well as of the antigenic relations of the individual microorganisms.

We thank Drs H Tlaskalová and J Kulda for their critical and stimulating comments, Dr Koutřová for supervising the English, and Mrs M Červeňová for typing the manuscript.

References

Immunotherapeutic effect of the lactobacillus vaccine, Solco Trichovac, in trichomoniasis is not mediated by antibodies cross reacting with Trichomonas vaginalis.

A Gombosová, P Demes and M Valent

doi: 10.1136/sti.62.2.107

Updated information and services can be found at:
http://sti.bmj.com/content/62/2/107

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/